Cyclophosphamide Treatment-Induced Leukopenia Rates In Anca-Associated Vasculitis are Influenced by Variant Cyp450 2C9 Genotypes

Abstract

Patients with variant CYP2C9 are at increased risk for cyclophosphamide-induced leukopenia but may have a better chance to respond to treatment.